Category: Endologix Inc.Syndicate content

Endologix wins IDE approval for aneurysm sealing system

January 3, 2014 by Chris Walker

Endologix launches a clinical trial after landing FDA Investigational Device Exemption for the Nellix endovascular aneurysm sealing system.

Endologix wins IDE approval for aneurysm sealing system

Endologix (NSDQ:ELGX) said it won FDA Investigational Device Exemption for its Nellix endovascular aneurysm sealing system, paving the way for a U.S. clinical trial.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Endologix offers $75M in convertible notes

December 5, 2013 by Chris Walker

Endologix is seeking to raise $75 million through sales of convertible notes with 2018 due dates.

Endologix offering $75 million in convertible notes

Endologix (NSDQ:ELGX) announced this week that the company is offering $75 million in convertible notes.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Cambridge Heart chairman, ex-CEO both resign | Personnel Moves

December 3, 2013 by Chris Walker

Ali Haghighi-Mood, the former president & CEO of Cambridge Heart, and chairman Roderick de Greef both resign for unnamed reasons.


Cambridge Heart (NSDQ:CAMH) said chairman and interim president Roderick de Greef and former president & CEO Ali Haghighi-Mood have both resigned from the medical device company.

Endologix posts Q3 sales surge but losses widen

November 6, 2013 by Chris Walker

Third-quarter sales surge for Endologix, but losses widen as it raises its earnings outlook and narrows its sales guidance for the rest of the year.

Endologix 3rd quarter results

Endologix (NSDQ:ELGX) posted sales growth of nearly 25% during the 3rd quarter, but losses widened by nearly 58%.

Irvine, Calif.-based Endologix posted losses of $9.5 million, or 14¢ per share, on sales of $33.3 million for the 3 months ended Sept. 30. That's a profit slide of 57.9% on sales growth of 24.6% compared with the same period last year.

Endologix shares gain 5 points in days following Q2 report

August 6, 2013 by Sony Salzman

Endologix beats the Street as the company's bottom line swings to the black during the 2nd quarter.

Endologix logo

Endologix (NSDQ:ELGX) beat Wall Street estimates by 2 cents and cut losses in the 2nd quarter, sending share prices up 5.3% to almost $16 in the days following the earnings results.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Iguana Healthcare Partners raises $54M investment fund | Wall Street Beat

July 3, 2013 by Arezu Sarvestani

Lifesciences investment firm Iguana Healthcare Partners raises $53.5 million in pooled interests. Wall Street Beat

New York-based lifesciences investment group Iguana Healthcare Partners filed an amended notice, reporting that the company has raised more than $53.5 million in pooled investment fund interests.

The funding, raised among 20 unnamed investors, will support Iguana's interests in pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services and healthcare information technology. +3 | The top 3 med-tech stories for June 19, 2013

June 19, 2013 by Brad Perriello

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.